Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Myeloproliferative Neoplasms MPN are blood cancers linked to a higher risk of blood clots. This research focuses on understanding how the presence of a genetic mutation called JAK2V617F in different blood cell types and endothelial cells relates to the risk of developing these clots. Researchers aim to identify specific patterns of this mutation in various cell populations that might help predict which patients are at higher risk for thrombosis. The study involves 120 patients diagnosed with either Polycythemia Vera PV or Essential Thrombocythemia ET. Blood samples will be collected to isolate platelets, red blood cells, granulocytes, and endothelial cells. Using digital PCR technology, the level of the JAK2V617F mutation will be measured in these cells. Patients with or without a history of thrombosis and different types of thrombosis will be compared to identify any associations with the mutation profiles. Participants will be involved at the time of diagnosis or within one year of diagnosis before starting cytoreductive treatment. Researchers will evaluate the mutation level in different blood cells and endothelial cells, assess the type of MPN, and measure the risk score for thrombosis. The main outcome is the history of thrombosis at diagnosis. This observational study does not involve treatment but collects blood samples and clinical data to better understand thrombosis risks in MPN patients.
Actively Recruiting
Researchers are studying ICU Acquired Weakness by evaluating whether early sitting out of bed in an arm-chair position improves functional recovery in patients who are ventilated in intensive care. This trial compares this early armchair positioning to a conservative strategy of sitting in bed, aiming to clarify if the armchair is essential for improving muscle and functional outcomes, as current guidelines do not strongly recommend this practice. Participants who have been awake with a certain alertness level RASS score between -1 and 1 for over 12 hours are randomly assigned to either daily chair sessions lasting at least 30 minutes or to no chair positioning. The chair sessions continue until ICU discharge or day 28, with careful monitoring of tolerance and a maximum session duration of 4 hours. The study follows patients through their ICU stay to assess recovery. During the study, researchers assess functional levels at ICU discharge or day 28, along with mobility scales, muscle strength scores, length of ICU and hospital stays, ventilator-free days, and mortality rates up to six months. Patients are monitored closely for safety and recovery progress throughout their ICU stay, with data collected to understand the impact of early armchair positioning on their health and function.
Actively Recruiting
Ventilator-associated pneumonia VAP is a common hospital-acquired infection in intensive care units linked to longer use of mechanical ventilation and the overuse of antibiotics. This trial evaluates two strategies for starting antibiotic treatment in patients suspected of having non-severe VAP immediate antibiotic therapy after sampling versus waiting for bacteriological confirmation before starting antibiotics. The study aims to understand the impact of these approaches on patient outcomes and antibiotic resistance. Participants are randomly assigned to one of two groups the usual care group, where antibiotics begin within one hour of randomization based on clinical judgment, or the conservative strategy group, where antibiotics are delayed until microbiological results confirm infection. If cultures are negative, antibiotics are stopped or not started. If confirmed, antibiotics targeting the identified bacteria are given for seven days. Treatment decisions consider local protocols and resistance risks. During the study, participants are closely monitored for 28 days to assess survival and duration of mechanical ventilation. Various clinical scores and infection-related outcomes are recorded, including organ failure, infection clearance, antibiotic use, and hospital stay length. The study also evaluates antibiotic resistance and adverse effects. Data are collected from randomization through ICU and hospital discharge, with a primary focus on death or ventilation status at day 28.
Actively Recruiting
Researchers are investigating the best noninvasive respiratory support method for patients in intensive care units ICUs who develop respiratory failure after planned removal of their breathing tube extubation. This condition affects about 20% of ICU patients, and many require reintubation, which is linked to high mortality rates. The study aims to compare whether alternating non-invasive ventilation NIV with high-flow nasal oxygen reduces death rates compared to high-flow nasal oxygen alone in these patients. The trial is a multicenter, randomized, controlled study where patients with post-extubation respiratory failure are assigned to one of two groups. One group receives continuous high-flow nasal oxygen treatment for 48 hours, while the other group receives NIV alternating with high-flow nasal oxygen during the same period. NIV involves pressure-support breathing with specific settings to help patients breathe, and the study ensures balance in patient groups based on carbon dioxide levels in the blood. Participants will be closely monitored with assessments including timing of death, reintubation events, days without ventilator use, length of ICU and hospital stay, and mortality at different time points up to 90 days. The main outcome measured is death rate 28 days after respiratory failure onset. The study includes clinical evaluations and blood gas tests to guide treatments and decisions. Participation duration includes the initial 48-hour treatment period and follow-up assessments extending to 90 days.
Actively Recruiting
Squamous cell carcinoma of the anus is a rare but increasingly common cancer, often linked to human papillomavirus HPV. For early-stage tumors, combined radiotherapy and chemotherapy with 5FU and mitomycin-C provide good outcomes, but advanced tumors have a poor prognosis with a high relapse rate. Researchers are studying a new approach combining induction chemotherapy with docetaxel, cisplatin, and 5FU mDCF followed by standard chemoradiotherapy to improve treatment results for locally advanced anal cancer T3-4 or N1. This is a randomized phase 3 trial comparing this new strategy to the current standard treatment. The study includes two groups one receives the usual chemoradiotherapy, which involves 33 radiotherapy sessions over 6.5 weeks combined with mitomycin-C and capecitabine chemotherapy taken on radiotherapy days. The other group starts with 4 cycles of mDCF chemotherapy given every two weeks before receiving the same chemoradiotherapy as the control group. Radiotherapy uses intensity-modulated external irradiation with a targeted boost to the tumor and involved lymph nodes. Participants will be followed after treatment with check-ups at 8 weeks, then every 4 months for two years, and every 6 months in the third year. Follow-up includes clinical exams and imaging scans CT and MRI. The main measure of success is disease-related event-free survival two years after treatment. Other outcomes include overall survival, colostomy-free survival, treatment side effects, tumor response, and quality of life. The total study duration for each participant may extend over several years including this follow-up period.
Actively Recruiting
Infected pilonidal sinus is a common condition that occurs more frequently in men, usually between the ages of 15 and 30. This trial evaluates a new radiofrequency treatment using the Fistura procedure for infected pilonidal sinus to measure its safety, effectiveness, and patient satisfaction. The study aims to address the limitations of traditional open wound surgery and newer laser techniques by using radiofrequency thermocoagulation, which has been used safely in treating anal fistulas. Participants will receive the radiofrequency treatment with fibers adapted for the size of the pilonidal sinus cavity. This method is believed to better destroy granulation tissue and assist healing. The study will monitor safety within 15 days after treatment and evaluate treatment efficiency and patient satisfaction at 1 month and 6 months post-treatment. Medical leave length will also be recorded. Participants will be assessed before and after treatment, including safety checks shortly after the procedure and follow-up visits to measure pain, healing, and satisfaction. The primary outcome focuses on safety within 15 days after treatment. Secondary outcomes include treatment efficacy at 6 months, pain levels, duration of medical leave, and satisfaction surveys. The total study period includes initial treatment and monitoring over 6 months to understand the treatments impact.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.
Actively Recruiting
Systemic sclerosis SSc is a rare autoimmune disease that causes skin thickening and can affect internal organs, leading to serious health issues. This research evaluates the safety and effectiveness of itacitinib, a drug targeting specific pathways involved in SSc, particularly the JAK-STAT pathway linked to fibrosis and inflammation. The study focuses on adults with diffuse SSc, a severe form with significant skin and organ involvement. Participants are randomly assigned to receive either 200 mg of oral itacitinib daily or a matching placebo for 360 days. The study is a phase II, randomized, controlled trial with quadruple masking to compare outcomes between these two groups. The trial assesses treatment effects on skin thickening and disease activity over the course of one year. During the study, participants undergo regular assessments including skin scoring modified Rodnan skin score, disease activity evaluations, and quality of life questionnaires at multiple time points up to 360 days. Safety is monitored through adverse event tracking and laboratory tests. The main outcome measured is the change in skin thickness after 360 days of treatment, helping researchers understand the potential impact of itacitinib on systemic sclerosis.
Actively Recruiting
Researchers are studying the potential benefits of outpatient care for patients with acute uncomplicated appendicitis treated by laparoscopic appendectomy. This research aims to compare outpatient care with conventional hospital care to see if outpatient care is not worse in terms of overall morbidity and mortality within 30 days after surgery. The study is motivated by the need to optimize care pathways, reduce hospital stays, improve patient satisfaction, and lower healthcare costs, especially important during the COVID-19 pandemic. The trial compares two treatment groups one receiving ambulatory appendectomy where surgery is done in an outpatient surgery unit and patients are discharged the same day, and the other receiving conventional appendectomy where surgery occurs in the digestive surgery department and patients stay overnight for observation before discharge. The study evaluates outcomes up to 30 days after surgery, including hospital stay length, rehospitalization rates, complications, re-interventions, patient satisfaction, quality of life, and economic impacts. Participants will undergo assessments before and after surgery, with monitoring of clinical outcomes, patient satisfaction, and quality of life at 7 and 30 days post-operation. Researchers will also track safety, the rate of conversion from outpatient to conventional care, and costs associated with each care pathway. The total study participation includes follow-up for 30 days after surgery to assess the main and secondary outcomes.
Actively Recruiting
Researchers are investigating the best way to manage treatment withdrawal of denosumab Dmab in women with postmenopausal osteoporosis. Denosumab is an effective treatment, but stopping it can cause a rebound effect, including increased bone turnover markers, loss of bone density, and a higher risk of vertebral fractures. This study aims to compare two strategies using zoledronate ZOL infusions to reduce these rebound effects after Dmab withdrawal. Participants receive an initial ZOL infusion six months after stopping denosumab. One group receives a second ZOL infusion guided by biomarker levels crosslaps if these reach a certain threshold within one year. The other group follows a standard treatment with a potential rescue second infusion at month 12 if there is an unfavorable outcome or high risk of fractures. This open-label randomized trial tests whether biomarker-driven additional treatment offers better protection against bone loss. During the study, participants will have bone mineral density BMD measured in the lumbar spine and hip at baseline, one year, and two years. Bone turnover markers and fractures will also be monitored regularly up to two years. The main outcome is maintaining lumbar BMD after one year of zoledronate treatment. Safety and treatment response will be assessed throughout the study duration, which includes follow-up visits at months 3, 6, 9, and 12.
1-10 of 12
1